

# Clinical Commissioning Policy Glucarpidase for the urgent treatment of toxic plasma methotrexate concentration due to delayed methotrexate elimination

**Publication date: March 2024 v3.0 (First Published January 2015, updated December 2022)**

## Commissioning position

### Summary

NHS England will commission glucarpidase for the urgent treatment of toxic plasma methotrexate concentration due to delayed methotrexate elimination in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

**Equality statement**

Promoting equality and addressing health inequalities are at the heart of NHS England’s values. Throughout the development of the policies and processes cited in this document, we have:

* Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
* Given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities.

## Executive summary

## Plain language summary

### About toxic plasma methotrexate concentration due to delayed methotrexate elimination

Methotrexate is an antifolate drug that is used alone or in combination with other drugs to treat a variety of cancers and autoimmune conditions (e.g. rheumatoid arthritis). It is administered over a wide dose range, which can be as low as 20 mg/m2 (milligrams per square metre) for maintenance therapy or between 1g/m2 and 12g/m2 (grams per square metre) when used as high dose therapy.

Patients receiving high-dose methotrexate therapy are at risk of developing acute renal dysfunction, induced by the precipitation of methotrexate and its metabolites, in the renal tubules. Acute renal dysfunction is a life-threatening complication and further delays the renal clearance of methotrexate, leading to elevated, and potentially toxic, plasma concentrations of the drug and the potential for additional methotrexate toxicities including myelosuppression, mucositis, hepatitis, and dermatitis.

### About current treatment

Patients receiving high-dose methotrexate therapy are treated with aggressive hydration and alkalinisation to improve the solubility of methotrexate, and with calcium folinate, a folate that can counteract the adverse effects of methotrexate. With this regimen, in combination with close patient monitoring, the incidence of methotrexate nephrotoxicity decreases from about 10% to approximately 1% to 2%. Despite the reduced incidence of methotrexate-induced toxicity, cases of severe and fatal nephrotoxicity still occur.

Glucarpidase is a licensed medication indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination. Glucarpidase reduces methotrexate concentration by >98% within 15 minutes of administration. It is a recombinant form of the bacterial enzyme carboxypeptidase G2 and works by rapidly hydrolysing methotrexate into inactive non cytotoxic metabolites. These are not eliminated by the kidney, providing an alternative clearance route in patients who have delayed renal elimination.

Glucarpidase is intended for use by paediatric and adult oncology and haematology consultants for treating children and adults receiving high-dose methotrexate chemotherapy who develop a significant deterioration in renal function after the start of the high dose methotrexate, have toxic plasma methotrexate concentrations and are at risk of life-threatening methotrexate-induced toxicities.

It is very unlikely that in any given year glucarpidase will be used for more than 20 patients. However, when it is required, it is needed urgently without time to seek funding approval through the Individual Funding Request route. Determining a national commissioning position in advance of its use would allow clinicians to manage patients appropriately in full knowledge of funding streams.

### **What we have decided**

NHS England has carefully reviewed the evidence to treat toxic plasma methotrexate concentration due to delayed methotrexate elimination with glucarpidase. We have concluded that there is enough evidence to make the treatment available at this time.

## Links and updates to other policies

## This policy follows the principles set out in the ethical framework that govern the commissioning of NHS healthcare and those policies dealing with the approach to experimental treatments and processes for the management of individual funding requests (IFR).

## Epidemiology and needs assessment

## Current usage data suggests demand for this product will be very low in the region of 5 to 10 patients a year (adults/paediatrics).

## Glucarpidase is needed for use by paediatric and adult oncology / haematology patients who develop a significant deterioration in renal function after the start of high dose methotrexate, have toxic plasma methotrexate concentrations and are at risk of life-threatening methotrexate-induced toxicities.

## Evidence summary

## NHS England has concluded that there is sufficient evidence to support a policy for the routine commissioning of this treatment for the indication.

## A number of uncontrolled phase II single arm studies and case reports have been

## published previously (1-3). However, more recently a pooled analysis of efficacy

## data from four multicentre single-arm compassionate-use clinical trials using

## protocols from 1993 to 2007 was published (4).

## Of 476 patients with renal toxicity and delayed methotrexate elimination who were

## treated with intravenous glucarpidase for rescue after high-dose methotrexate, 169

## patients had at least one preglucarpidase (baseline) plasma methotrexate

## concentration greater than 1 micromol/L and one postglucarpidase methotrexate

## concentration measurement by high-performance liquid chromatography and were

## included in the efficacy analysis; renal recovery was assessed in 436 patients who

## had at least one recorded preglucarpidase and postglucarpidase serum creatinine

## concentration measurement.

## Efficacy was defined as rapid and sustained clinically important reduction (RSCIR)

## in plasma methotrexate concentration, with a concentration of 1 micromol/L or lower at all

## postglucarpidase determinations. Median age of efficacy-evaluable patients was 20

## years (range 5 weeks-84 years). Osteosarcoma (36%), non-Hodgkin lymphoma

## (27%), and acute lymphoblastic leukaemia (20%) were the most frequent underlying

## diagnoses. Median preglucarpidase serum methotrexate was 11.7 micromol/L. At the first

## (median 15 minutes) through the last (median 40 hours) postglucarpidase

## measurement, plasma methotrexate concentrations demonstrated consistent 99%

## median reduction. RSCIR was achieved by 83 (59%) of 140 patients. A total of 64%

## of patients with renal impairment greater than or equal to Common Terminology

## Criteria for Adverse Events grade 2 recovered to grade 0 or 1 at a median of 12.5

## days after glucarpidase administration.

## The authors concluded that Glucarpidase caused a clinically important 99% or

## greater sustained reduction of serum methotrexate levels and provided noninvasive

## rescue from methotrexate toxicity in renally impaired patients.

## Paediatric patients

## Experience with glucarpidase in children has been published in abstract (5). From

## November 1993 through June 2009, 232 paediatric patients experiencing renal

## toxicity and delayed elimination of methotrexate (methotrexate) were treated with

## glucarpidase (50 units/kg intravenously) in compassionate use trials conducted in

## the United States and Europe.

## Of the 232 paediatric patients, 89 were < 12 years; the youngest was 5 weeks. Fifty-four percent were male. Forty-seven percent were treated for osteogenic sarcoma,

## 31% for ALL, 18% for non-Hodgkin lymphoma, and 4% for other malignancies. The

## median pre-glucarpidase methotrexate concentration was 34 micromol/L. Seventy

## percent of patients received a single dose of glucarpidase, 28% received 2 doses,

## and 2% received 3 doses.

## Sixty-seven patients had methotrexate concentrations determined by central

## laboratory HPLC assay. At the first measurement (median 15 minutes postglucarpidase; range: 10 - 30 minutes) serum methotrexate concentration was

## reduced by ≥ 95% in 91% of patients. Eighty-four percent of patients had a ≥ 95%

## reduction at the last measurement (median 48 hours post-glucarpidase).

## In the 201 patients with pre-glucarpidase renal impairment measured as NCI

## Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher, 75%

## recovered to Grade 0 or 1 after a median of 10 days post-glucarpidase.

## Glucarpidase was well-tolerated overall, but side effects included paraesthesia

## (2.2%), flushing (1.7%), headache (1.3%), burning sensation (1.3%), and feeling hot

## (1.3%). Thirteen patients died during the follow-up period of causes unrelated to

## glucarpidase, as judged by the treating physician.

## Glucarpidase is the treatment recommendation within the UKALL2011 (trial for

## acute lymphoblastic leukaemia and lymphoma (EudraCT no. 2010-020924-22))

## when a child has: raised Methotrexate levels at specified time points post high dose

## Methotrexate infusion, serum creatinine rises >100% within 24 hours of infusion,

## delayed excretion when plasma methotrexate levels plateau.

## Alternative treatments

## There are no other drugs currently used for the same indication. Haemodialysis is a

## possible option if renal failure occurs. However, this must be repeated continuously

## or daily, in order to reduce the methotrexate concentration to non-toxic concentrations.

## The use and efficacy of dialysis-based methods of methotrexate removal in patients

## with HD- methotrexate-induced renal dysfunction has been reviewed (6). The

## review included 49 patients from 30 publications. The most frequently used single

## methods reviewed were haemodialysis (n=10), high-flux haemodialysis (n=9) and

## charcoal haemoperfusion or charcoal haemofiltration (n = 7) with 16 patients treated

## with multiple modalities. Dialysis-based methods were used for up to 14 days.

## Peritoneal dialysis alone resulted in only a minimal decrease in plasma

## methotrexate concentrations. The use of other single-modality methods of

## methotrexate removal resulted in a median decrease in plasma methotrexate

## concentration of 52% (range, 26 - 82%). High-flux haemodialysis resulted in the

## greatest decrease in plasma methotrexate concentrations (median 75.5%; range 42

## - 94%) within the shortest period of time (median 4 hours; range 4 - 12 hours). Only

## 3 patients had a > 90% decrease in methotrexate concentration with the use of

## single method in one dialysis session. However, a major limitation on the use of

## dialysis-based methods is the marked rebound in plasma methotrexate

## concentrations that can occur when the dialysis is stopped. Rebound increases in

## the post-dialysis plasma methotrexate concentration were in the range of 10 - 221%

## of the post-procedure methotrexate concentration and 90 - 100% of the pre-procedure

## methotrexate concentration.

## Implementation Criteria

### Before patients receive high-dose methotrexate, there should be formal checks to ensure the patient has normal renal function and there is good hydration / alkalinisation of urine. Before using glucarpidase, all other supportive measures must have been optimised, such as use of fluids and calcium folinate.

### Glucarpidase will be routinely funded for the treatment of adults and children receiving high-dose methotrexate chemotherapy (doses > 1g/m2) who have a toxic plasma methotrexate concentration due to delayed methotrexate elimination caused by a significant deterioration in renal function and, despite rescue measures, are at risk of life-threatening methotrexate induced toxicities.

### A significant deterioration in renal function is regarded as a serum creatinine that is at least 1.5 times the upper limit of normal, or the presence of oliguria.

### Defining a toxic methotrexate concentration is complicated by the regimen used and the time at which the concentration is tested. Clinicians should refer to the Summary of Product Characteristics for guidance on defining toxic concentrations. Implementation of a local policy that accounts for local logistics is recommended, so that clinicians can refer to this for guidance. However, patients must have a dangerously high plasma methotrexate concentration, despite all standard rescue measures and delayed methotrexate elimination due to a significant deterioration in renal function. For children refer to paediatric specific chemotherapy protocol.

### Dose

### The recommended dose and schedule for glucarpidase is as a single intravenous injection of 50 units/kg. Multiple doses are not permitted under this policy.

### Patient pathway

Glucarpidase has been used in NHS England to urgently treat toxic methotrexate concentrations that have occurred during cancer chemotherapy. It may be used in any patient receiving high-dose methotrexate therapy who develops toxic methotrexate concentrations due to delayed methotrexate elimination, caused by a significant deterioration in renal function and who is at risk of life-threatening complications.

**Governance arrangements**

Provider organisations must register all patients using prior approval software and ensure monitoring arrangements are in place to demonstrate compliance against the criteria as outlined.

Mechanism for funding

## Methotrexate chemotherapy is funded by NHS England.

Glucarpidase for the urgent treatment of toxic methotrexate concentration due to delayed methotrexate elimination is commissioned and funded by NHS England Specialised Commissioning under existing arrangements for the provision of specialised services in line with this Clinical Commissioning Policy

## **Audit requirements**

## Collation of patient details and outcome by Acute Trust and reported to the NHS England Area Team.

## Policy review date

This document will be reviewed when information is received which indicates that the policy requires revision. If a review is needed due to a new evidence base, then a new Preliminary Policy Proposal needs to be submitted by contacting [england.CET@nhs.net](mailto:england.CET@nhs.net).

Our policies provide access on the basis that the prices of therapies will be at or below the prices and commercial terms submitted for consideration at the time evaluated. NHS England reserves the right to review policies where the supplier of an intervention is no longer willing to supply the treatment to the NHS at or below this price and to review policies where the supplier is unable or unwilling to match price reductions in alternative therapies.

## References

1. Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. British journal of cancer. 2005;92(3):480-7.

2. Schwartz S, Borner K, Müller K, Martus P, Fischer L, Korfel A, et al. Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients with Renal Dysfunction and Delayed Methotrexate Elimination After High- Dose Methotrexate Therapy. The Oncologist. 2007;12(11):1299-308.

3. Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, et al. Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome. Journal of Clinical Oncology. 2010;28(25):3979-86.

4. Widemann BC, Schwartz S, Jayaprakash N, Christensen R, Pui CH, Chauhan N, et al. Efficacy of Glucarpidase (Carboxypeptidase G2) in Patients with Acute Kidney Injury After High-Dose Methotrexate Therapy. Pharmacotherapy. 2013.

5. Howard SC, Widemann BC, Chauhan N, Daugherty C, King TR, Jayaprakash N, et al., editors. Pediatric clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity. American Society of Pediatric Hematology Oncology; 2012 May 9-12; New Orleans, Louisiana.

6. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703.